Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency

Journal of Endocrinology

Volumn 176, Issue 2, 2003, Pages 237-246

  Takeda, K ^a   Toda, K ^a   Saibara, T ^a   Nakagawa, M ^a   Saika, K ^a   Onishi, T ^a   Sugiura, T ^a   Shizuta, Y ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AROMATASE; CHOLESTEROL; CYTOCHROME P450; ESTRADIOL; ESTROGEN; FIBRIC ACID DERIVATIVE; GLUCOSE; INSULIN; TESTOSTERONE; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL;

ANDROGEN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; BODY WEIGHT; CELL METABOLISM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME DEFICIENCY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; KNOCKOUT MOUSE; LIPID METABOLISM; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

AGING; ANIMALS; AROMATASE; BEZAFIBRATE; BLOOD GLUCOSE; CHOLESTEROL; ESTRADIOL; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; OBESITY; TESTOSTERONE; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0037291609     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1760237     Document Type: Review

References (41)

1. Balfour J, McTavish D & Heel RC 1990 Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs 40 260-290.
2. Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, Jensen MD, Schwenk WF & Rizza RA 2000 Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 49 272-283.
3. Boujrad N, Vidic B, Gazouli M, Culty M & Papadopoulos V 2000 The peroxisome proliferator perfluorodecanoic acid inhibits the peripheral-type benzodiazepine receptor (PBR) expression and hormone-stimulated mitochondrial cholesterol transport steroid formation in Leydig cells. Endocrinology 141 3137-3148.
4. Braissant O, Foufelle F, Scotto C, Dauca M & Wahli W 1995 Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPAR α, β and γ in the adult rat. Endocrinology 137 354-366.
5. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ & Kahn CR 1998 A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Molecular Cell 2 559-569.
6. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS & Simpson ER 1997 Effect of testosterone and estradiol in a man with aromatase deficiency. New England Journal of Medicine 337 91-95.
7. Couse JF & Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocrine Reviews 20 358-417.
8. DeFronzo RA 1997 Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Review 5 177-269.
9. Faustini-Fustini M, Rochira V & Carani C 1999 Oestrogen deficiency in men: where are we today? European Journal of Endocrinolqqy 140 111-129.
10. Fisher CR, Graves KH, Parlow AF & Simpson ER 1998 Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp 19 gene. PNAS 95 6965-6970.
11. Friedl KE, Jones RE, Hannan CJ Jr & Plymate SR 1989 The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. Journal of Clinical Endocrinology and Metabolism 68 971-975.
12. Gazouli M, Yao ZX, Boujrad N, Corton JC, Culty M & Papadopoulos V 2002 Effect of peroxisome proliferators on Leydig cell peripheral-type benzodiazepine receptor gene expression, steroidogenesis: role of the peroxisome proliferator-activator receptor α. Endocrinology 143 2571-2583.
13. Grumbach MM & Auchus RJ 1999 Estrogen: consequences and implications of human mutations in synthesis and action. Journal of Clinical Endocrinology and Metabolism 84 4677-4694.
14. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart GC, Berge RK & Staels B 2000 Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. Journal of Biological Chemistry 275 16638-16642.
15. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB & Cooke PS 2000 Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. PNAS 97 12729-12734.
16. Isemann I & Green S 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 645-650.
17. Jones MEE, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S & Simpson ER 2000 Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. PNAS 97 12735-12740.
18. Kahn CR 1994 Insulin action, diabetogenes, and the cause of type Il diabetes. Diabetes 43 1066-1084.
19. Kawamori R, Matsuhisa M, Kinoshita J, Mochizuki K, Niwa M, Arisaka T, Ikeda M, Kubota M, Wada M, Kanda T, Ikebuchi M, Tohdo R & Yamasaki Y 1998 Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp OGL Study Group. Diabetes Research and Clinical Practice 41 35-43.
20. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM & Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPARγ). Journal of Biological Chemistry 270 12953-12956.
21. Lewis GF, Carpentier A, Vranic M & Giacca A 1999 Resistance to insulin's acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes. Diabetes 48 570-576.
22. Marin P, Oden B & Björntorp P 1995 Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. Journal of Clinical Endocrinology and Metabolism 80 239-243.
23. Mauras N, Welch S, Rini A & Haymond MW 1998 Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: a metabolic study. Journal of Clinical, Endocrinology and Metabolism 83 1900-1905.
24. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA & Kahn CR 2000 Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Molecular Cell 6 87-97.
25. Morishima A, Grumbach MM, Simpson ER, Fisher C & Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and physiological role of estrogens. Journal of Clinical Endocrinology and Metabolism 80 3689-3698.
26. Nabulsi AM, Folsom AR, White A, Patsch W, Heiss G, Wu KK & Szklo M 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New England Journal of Medicine 328 1069-1075.
27. Nemoto Y, Toda K, Ono M, Fujikawa-Adachi K, Saibara T, Onishi S, Enzan H, Okada T & Shizuta Y 2000 Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. Journal of Clinical Investigation 105 1819-1825.
28. Pamela DS, Garmey JC & Veldhuis JD 2002 Putative activation of the proliferator-activated receptor γ impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biology of Reproduction 66 190-198.
29. Peiris AN, Aiman EJ, Drucker WD & Kissebah AH 1989 The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women. Journal of Clinical Endocrinology and Metabolism 68 715-720.
30. Polderman KH, Gooren LJG, Asscheman H, Bakker A & Heine RJ 1994 Induction of insulin resistance by androgens and estrogens. Journal of Clinical Endocrinology and Metabolism 79 265-271.
31. Saltiel AR & Olefsky JM 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45 1661-1669.
32. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B & Auwerx J 1996 PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO Journal 15 5336-5348.
33. Shozu M, Akasofu K, Harada T & Kubota Y 1991 A new cause of female pseudohermaphroditism: placental aromatase deficiency. Journal of Clinical Endocrinology and Metabolism 72 560-566.
34. Simpson ER 2000 Genetic mutations resulting in loss of aromatase activity in humans and mice. Journal of the Society for Gynecologic Investigation 7 S18-S21.
35. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB & Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. New England Journal of Medicine 331 1056-1061.
36. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J & Auwerx J 1995 Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. Journal of Clinical Investigation 95 705-712.
37. Toda K, Okada T, Takeda K, Akira S, Saibara T, Shiraishi M, Onishi S & Shizuta Y 2001a Oestrogen at neonatal stage is critical for reproductive ability of male mice as revealed by supplementation with 17β-oestradiol to aromatase (CYP19) gene knockout mice. Journal of Endocrinology 168 455-463.
38. Toda K, Takeda K, Akira S, Saibara T, Okada T, Onishi S & Shizuta Y 2001b Alterations in hepatic expression of fatty-acid metabolizing enzymes in ArKO mice and their reversal by treatment with 17β-estradiol or a peroxisome proliferator. Journal of Steroid Biochemistry and Molecular Biology 79 11-17.
39. Toda K, Takeda K, Okada T, Akira S, Saibara T, Kaname T, Yamamura K, Onishi S & Shizuta Y 2001c Targeted disruption of the aromatase P450 gene (Cyp19) in mice and their ovarian and uterine responses to 17β-oestradiol. Journal of Endocrinology 170 99-111.
40. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V & Sacks FM 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine 325 1196-1204.
41. Yoshikawa T, Toda K, Nemoto Y, Ono M, Iwasaki S, Maeda T, Saibara T, Hayashi Y, Miyazaki E, Hiroi M, Enzan H, Shizuta Y & Onishi S 2002 Aromatase-deficient (ArKO) mice are retrieved from severe hepatic steatosis by peroxisome proliferator administration. Hepatology Research 22 278-287.